Company Filing History:
2 out of 2,405 
1 out of 56 
Years Active: 2021-2024
Title: Innovations by Shaopeng Huang in Cancer Treatment
Introduction
Shaopeng Huang is a notable inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for cancer treatment. With a total of two patents to his name, Huang's work is at the forefront of medical innovation.
Latest Patents
Huang's latest patents include the development of anti-PD-1 antibodies, which are designed to target and bind to the PD-1 protein, playing a crucial role in the immune response against cancer and infectious diseases. His second patent focuses on anti-PD-1/LAG3 bispecific antibodies, which combine the targeting capabilities of both PD-1 and LAG3, offering new avenues for cancer therapy.
Career Highlights
Throughout his career, Huang has worked with prominent companies in the biotechnology sector, including Merck Sharp & Dohme Corporation and Zymeworks Inc. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in immunotherapy.
Collaborations
Huang has collaborated with esteemed colleagues such as Laurence Fayadat-Dilman and Veronica Juan. These partnerships have further enhanced his research and development efforts in the field of cancer treatment.
Conclusion
Shaopeng Huang's innovative work in the development of antibodies represents a significant advancement in the fight against cancer. His contributions are paving the way for new therapeutic options that could improve patient outcomes.